𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Recent advances in the treatment of thromboembolic diseases: Venous thromboembolism

✍ Scribed by Y.K. Agrawal; Hitesh Vaidya; Hardik Bhatt; Kuntal Manna; Pathik Brahmkshatriya

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
342 KB
Volume
27
Category
Article
ISSN
0198-6325

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Venous thromboembolic diseases are the major concern of rising cost of healthcare and are commonest health problem across the globe. Both genetic and acquired risk factors are believed to be strongly linked with these diseases. Commonly encountered problems to the therapy include dose fixing and routine monitoring, yet some serious problems of bleeding also necessitate the immediate need to develop new agents. The review is primarily concerned with the new developments in the treatment of thromboembolic diseases. Therapeutic applications of anticoagulants, antiplatelets, and thrombolytics have been discussed in enough detail. Β© 2007 Wiley Periodicals, Inc. Med Res Rev, 27, No. 6, 891–914, 2007

πŸ“œ SIMILAR VOLUMES

ChemInform Abstract: Recent Advances in
ChemInform Abstract: Recent Advances in the Treatment of Thromboembolic Diseases: Venous Thromboembolism
✍ Y. K. Agrawal; Hitesh Vaidya; Hardik Bhatt; Kuntal Manna; Pathik Brahmkshatriya πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons βš– 15 KB πŸ‘ 2 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a β€œFull Text” option. The original article is trackable v

Inhalable liposomes of low molecular wei
Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism
✍ Shuhua Bai; Fakhrul Ahsan πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 456 KB

This study tests the feasibility of inhalable pegylated liposomal formulations of low molecular weight heparin (LMWH) for treatment of two clinical manifestations of vascular thromboembolism: deep vein thrombosis (DVT) and pulmonary embolism (PE). Conventional distearoyl-sn-glycero-3-phosphoethanola

Underutilization of evidence-based strat
Underutilization of evidence-based strategies in the diagnosis and treatment of venous thromboembolism among trainees
✍ Vibhu Sharma; Charles Koczka; Conrad Fischer πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 121 KB

## Abstract ## BACKGROUND: The knowledge and attitude of trainees toward the use of prediction rules in the diagnosis of venous thromboembolism (VTE) is understudied. The extent of knowledge as far as imaging strategies in the setting of VTE and use of low molecular weight heparin (LMWH) among tra

Anticoagulation for the initial treatmen
Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer : A systematic review
✍ Elie A. Akl; Sandeep Rohilla; Maddalena Barba; Francesca Sperati; Irene Terrenat πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 312 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. The authors compared the relative efficacy and safety of low‐ molecular‐weight heparin (LMWH) and unfractionated heparin (UFH) for the initial treatment of venous thromboembolism (VTE) between patients with and without cancer. ## METHODS. By using Cochrane methodology

Venous thromboembolism in the patient wi
Venous thromboembolism in the patient with cancer : Focus on burden of disease and benefits of thromboprophylaxis
✍ Gary H. Lyman πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 219 KB πŸ‘ 1 views

## Abstract Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in patients with cancer. The risk of VTE varies over the natural history of cancer, with the highest risk occurring during hospitalization and after disease recurrence. Patient and disease characteristics are